Kleberg Foundation Report issue

Foundation

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Alternative names

Kleberg Foundation

Active Ingredients

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 0
  • # of Trial APIs: 0